Puterizumab
Phase 2Monoclonal antibody
Puterizumab is one of 54 small molecule programs targeting Metastasis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
64 competitors in Metastasis
#DrugCompanyPhaseTrials
1Femara
NovartisApproved
Norvir
AbbVieApproved
Neoral
NovartisApproved
Lynparza
AstraZenecaApproved
Tukysa
PfizerApproved
Taxol
TevaApproved
Trexall
Jazz PharmaceuticalsApproved
Camptosar
PfizerApproved
Gemzar
Johnson & JohnsonApproved
Keytruda
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Puterizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- SSir Run Run Shaw Hospital